Key result
APOA5 56G carriers exhibited a greater reduction in fasting triglycerides and increase in HDL-C after 3 weeks of fenofibrate treatment compared to noncarriers.
Why the study?
Does the response to fenofibrate therapy differ based on APOA5 genetic variants in men and women?
Cohort (n=791)
Does the response to fenofibrate therapy differ based on APOA5 genetic variants in men and women?
Carriers of the APOA5 56G variant derive significantly greater triglyceride-lowering and HDL-raising benefits from fenofibrate therapy compared to noncarriers.
Answers are grounded in this paper and cite their sources.
APOA5 56G was associated with enhanced fenofibrate response; hypothesis-generating and should not yet change practice.
OBJECTIVE: Apolipoprotein A5 (APOA5) is a key determinant of plasma triglyceride (TG) concentrations. Genetic variation at the APOA5 locus could be responsible for some of the observed differences in response to fenofibrate therapy. METHODS AND RESULTS: We examined the association between tag SNPs (-1131T>C and 56C>G) at APOA5 and TG and HDL-C response to fenofibrate and a postprandial lipid challenge in 791 men and women participating in the GOLDN study. After 3-week drug treatment, APOA5 56G carriers displayed significant decrease in TG (P=0.006), and increase in HDL-C (P=0.002) levels relative to their basal values in the fasting state when compared with noncarriers (a TG reduction of -35.8+/-2.8% versus -27.9+/-0.9% and a HDL-C increase of 11.8+/-1.3% versus 6.9+/-0.5%, respectively). In the postprandial lipemia after a fat load, the 56G carriers showed a significant decrease in the area under curve for TG and increase for HDL-C than the noncarriers. These diverse beneficial responses of 56G carriers to fenofibrate were further characterized by a higher increase in large LDL-C concentrations and LDL size. On the other hand, subjects with different APOA5-1131T>C genotypes showed no significant response to fenofibrate intervention. CONCLUSION: This study suggests that the APOA5 56G carriers benefited more from the fenofibrate treatment than noncarriers in lowering plasma TG and increasing HDL-C levels.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2007) reported a cohort. APOA5 56G carrier status vs. APOA5 56G noncarriers was evaluated on Triglyceride reduction (p=0.006). APOA5 56G carriers exhibited a greater reduction in fasting triglycerides and increase in HDL-C after 3 weeks of fenofibrate treatment compared to noncarriers.
Synapse has enriched 10 related papers. Consider them for comparative context: